Boehringer Ingelheim Press Releases

Metacam® for pigs now also available as oral suspension

Boehringer Ingelheim launches PCV2 vaccine in Russia

Boehringer Ingelheim announces results of phase III data showing that linagliptin significantly lowered blood glucose with an excellent safety and tolerability profile

Boehringer Ingelheim announces results of phase III data showing that linagliptin significantly lowered blood glucose with an excellent safety and tolerability profile

Boehringer Ingelheim receives European approval for two new strengths for the once daily tablet formulation of Mirapexin®/Sifrol® prolonged-release for the treatment of Parkinson’s disease

Boehringer Ingelheim Comments on June 18th FDA Advisory Committee Meeting

Boehringer Ingelheim affirms safety of telmisartan with an analysis of 50,000 patients and strongly disagrees with the publication of Sipahi et al in Lancet Oncology June 2010

Dabigatran etexilate as effective and safe as enoxaparin in preventing venous thromboembolism (VTE) after total hip replacement surgery and significantly reduced the combined endpoint of major VTE and VTE-related death

Boehringer Ingelheim receives positive opinion for FLEXcombo® in the European Union

Boehringer Ingelheim’s lead investigational oncology compound BIBW 2992 demonstrates potential as a next generation treatment for non-small cell lung cancer and head-and-neck cancer

Women with hypoactive sexual desire disorder (HSDD) report that flibanserin increased their sexual desire and reduced associated distress

World’s No. 1 selling laxative - New study results on Dulcolax® confirm efficacy and safety

Boehringer Ingelheim and Micromet announce global collaboration for multiple myeloma BiTE antibody

Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in R&D / market launch of five innovative medicines planned

Topping-out ceremony at Boehringer Ingelheim – production site for innovative anticoagulant is being expanded

Boehringer Ingelheim announces successful completion of a tender offer to acquire outstanding shares in SSP Co., Ltd.

Boehringer Ingelheim launches Global Venture Fund to foster innovation in life sciences

Dabigatran etexilate shows greater reductions than warfarin in stroke in patients with atrial fibrillation across all stroke risk groups